After a single intramuscular dose of flunitrazepam 0.015 mg kg-' (n = 14) in women 37 to 41 weeks pregnant, the concentrations in the umbilical artery and amniotic fluid were significantly lower than in maternal venous plasma. Although the difference between the maternal venous and umbilical venous plasma concentrations was not significant, the mean fetomaternal ratio was 0.7. The plasma protein binding of flunitrazepam was 80 + 4% in the mother and 79 ± 5% in the umbilical circulation. Both mothers and midwives subjectively estimated intramuscular flunitrazepam as a valuable sedative-anxiolytic agent during the first stage of labour.
Introduction
The primary aims of the use of benzodiazepines during labour are to ensure that the mothers are subjectively without fear and anxiety about the pain and other consequences of labour. In addition, these agents can relax the pelvic musculature, may decrease the amount of pethidine needed, and are able to inhibit eclamptic convulsions (Kanto, 1982) . Flunitrazepam's prominent anxiolytic, sedative, and amnesic actions seem to be very useful during delivery (Kanto et al., 1979a,b; Kanto, 1982) . Furthermore, unlike other benzodiazepine derivatives, its placental transfer after a single maternal oral dose, both in early and late pregnancy, seems to be retarded (Kanto et al., 1979b (Table 2 ). All except one (6 at 1 min) Apgar scores at 1 and 5 min were 8 or better.
Discussion
The present results confirm our earlier findings on the peculiar kinetic properties of flunitrazepam during labour (Kanto et al., 1979b) . The (Cano et al., 1977; Kanto et al., 1981; Kangas et al., 1982) . There is a close correlation between the drug effect and plasma concentration during the first 12 h after an oral drug intake (first and second compartments), but there never was a high correlation between clinical effect and the level in the third compartment (Cano et al., 1977; Amrein et al., 1979) . The foetus is considered a 'deep compartment' (third compartment) which equilibrates slowly with the maternal compartment (Levy & Hayton, 1973) . Thus, the foetal plasma concentrations could lag behind the maternal ones as the mother eliminates the drug (Kanto et al., 1979b) . The even lower levels in the amniotic fluid are in favour of this model. However, another possible explanation is rapid foetal tissue uptake of the lipophilic flunitrazepam which was reflected as the low umbilical levels of the drug. Both patients and midwives considered intramuscular flunitrazepam as a valuable agent in decreasing anxiety during the first stage of labour. In this respect, it was thought to offer a good alternative to the routine use of diazepam.
In conclusion, due to the significantly lower levels in the fetal circulation, flunitrazepam seems to be a more useful derivative during pregnancy than other benzodiazepines (Kanto, 1982) . This opinion is based, however, mainly on kinetic data and, therefore, neurobehavioural studies are warranted in this respect. Similarly, after a single maternal oral dose, the concentrations in the breast milk have shown to be lower than those in the maternal plasma (Kanto et al., 1979b) .
Our favourable opinion applies particularly to a single dose or intermittent use of flunitrazepam. Due to its long elimination half-life, flunitrazepam may accumulate in the fetus and milk during long-term treatment (Kanto, 1982) . Thus high or repeated doses of this nitrobenzodiazepine derivative should be avoided during pregnancy and lactation. 
